Meet the volunteer consultants who support UMC with clinical expertise in our signal detection process.
UMC is fortunate to have the assistance of experienced international scientists and clinicians in the signal detection process. The Signal Review Panel consists of expert volunteers, often with institutional affiliations in government or academia.
Medicine-adverse effect combinations selected for further review during UMC’s screenings of VigiBase may be sent to members of the Signal Review Panel for in-depth assessment (read more about UMC’s signal detection process here). Members investigate the VigiBase case reports, review the literature, and consider the strength of evidence for the adverse effect being caused by the suspected medicine. The objective of this assessment is to provide data and arguments so that a decision can be made as to whether or not there is a credible signal to be communicated.
A signal is communicated as a summary report published in SIGNAL and subsequently in WHO Pharmaceuticals Newsletter. Some UMC signals are also the subject of research papers or posters published or displayed elsewhere.
Dr Ariel E Arias, Canada, Infectious diseases & Biotherapeutics
Prof P O Lundberg, Sweden